thor: impact of fgfr3 alterations in muc on subtype and outcomes with erdafitinib vs pembrolizumab
Published 2 months ago • 46 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
3:37
phase iii thor study: erdafitinib vs. pembrolizumab in fgfr-altered advanced or metastatic uc
-
1:47
thor: erdafitinib in metastatic urothelial cancer with fgfr alterations
-
17:27
new fda-approved therapy for targeting fgfr alterations in advanced urothelial cancer
-
46:19
targeting fgfr in urothelial carcinoma
-
1:38
orif of left and right arms
-
3:50
what is fgfr, and could it be a valuable target for patients with lung cancer?
-
2:01
fgfr mutations
-
5:16
the future of fgfr inhibitor treatment
-
1:40
liquid biopsy analysis of fgfr3 and pik3ca for disease surveillance in bladder cancer
-
2:48
fgfr inhibitors in bladder cancer
-
7:27
infigratinib for cca
-
7:20
thulium discussion | dr grunert - aua
-
1:12
ohmite metal foil low value power resistors fc4t series | tech specs
-
3:53
fet series system wrench
-
1:58
bone is gold - axiom x3® tandheelkundig implantaat
-
1:02
cordless impact wrench/drivers. controllable raw power. adjustable torques.
-
0:49
1735: fgfr3 or dystrophin
-
2:11
advanced orthotics with multi jet fusion and invent medical | hp 3d printing | hp
-
2:29
additional insights: experience with fgfr inhibitors in bladder cancer